P2 receptor-mediated signaling in the physiological and pathological brain: from development to aging and diseas
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Mut-Arbona, Paula
- dc.contributor.author Sperlágh, Beáta
- dc.date.accessioned 2025-04-29T09:45:05Z
- dc.date.available 2025-04-29T09:45:05Z
- dc.date.issued 2023
- dc.description.abstract The purinergic pathway mediates both pro-inflammatory and anti-inflammatory responses, whereas the breakdown of adenosine triphosphate (ATP) is in a critical equilibrium. Under physiological conditions, extracellular ATP is maintained at a nanomolar concentration. Whether released into the medium following tissue damage, inflammation, or hypoxia, ATP is considered a clear indicator of cell damage and a marker of pathological conditions. In this overview, we provide an update on the participation of P2 receptor-mediated purinergic signaling in normal and pathological brain development, with special emphasis on neurodevelopmental psychiatric disorders. Since purinergic signaling is ubiquitous, it is not surprising that it plays a prominent role in developmental processes and pathological alterations. The main aim of this review is to conceptualize the time-dependent dynamic changes in the participation of different players in the purinome in shaping the normal and aberrant developmental patterns and diseases of the central nervous system over one's lifespan. This article is part of the Special Issue on "Purinergic Signaling: 50 years".en
- dc.description.sponsorship This work was supported by the Hungarian Research and Development Fund [grant number 131629 to B.S.], the Hungarian Brain Research Program [grant number NAP2022-I-1/2022 to B.S.], the Recovery and Resilience Facility of the European Union within the framework of Programme Széchenyi Plan Plus [grant number RRF-2.3.1-21-2022-00011, National Laboratory of Translational Neuroscience and grant number RRF-2.3.1-21-2022-00015, National Laboratory of Drug Research and Development to B.S.], and the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska Curie grant [grant agreement number 766124 to P.M.A and B.S.].en
- dc.format.mimetype application/pdf
- dc.identifier.citation Mut-Arbona P, Sperlágh B. P2 receptor-mediated signaling in the physiological and pathological brain: from development to aging and disease. Neuropharmacology. 2023 Aug;233:109541. DOI: 10.1016/j.neuropharm.2023.109541
- dc.identifier.doi http://doi.org/10.1016/j.neuropharm.2023.109541
- dc.identifier.issn 0028-3908
- dc.identifier.uri http://hdl.handle.net/10230/70237
- dc.language.iso eng
- dc.publisher Elsevier
- dc.relation.ispartof Neuropharmacology. 2023 Aug;233:109541
- dc.relation.projectID info:eu-repo/grantAgreement/EC/H2020/766124
- dc.rights © 2023 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/bync-nd/4.0/
- dc.subject.keyword Purinergic receptorsen
- dc.subject.keyword Developmenten
- dc.subject.keyword Neurodevelopmental diseasesen
- dc.subject.keyword Pathologyen
- dc.subject.keyword Physiologyen
- dc.subject.keyword P2Xen
- dc.subject.keyword P2Yen
- dc.title P2 receptor-mediated signaling in the physiological and pathological brain: from development to aging and diseasen
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion